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The ability of natural-killer cells to regulate
adaptive immunity is not well understood. Here
we define an interaction between the class Ib
major histocompatibility complex (MHC) mole-
cule Qa-1–Qdmon activated T cells responsible
for adaptive immunity and CD94–NKG2A inhib-
itory receptors expressed by natural-killer cells
by using Qa-1-deficient and Qa-1 knockin mice
containing a point mutation that selectively
abolishes Qa-1–Qdm binding to CD94–NKG2A
receptors. The Qa-1–NKG2A interaction pro-
tected activated CD4+ T cells from lysis by
a subset of NKG2A+ NK cells and was essential
for T cell expansion and development of im-
munologicmemory. Antibody-dependent block-
ade of this Qa-1–NKG2A interaction resulted in
potent NK-dependent elimination of activated
autoreactive T cells and amelioration of exper-
imental autoimmune encephalomyelitis. These
findings extend the functional reach of the
NK system to include regulation of adaptive
T cell responses and suggest a new clinical
strategy for elimination of antigen-activated
T cells in the context of autoimmune disease
and transplantation.
INTRODUCTION
There is increasing evidence that maintenance of immu-
nological self-tolerance is an active process that requires
the participation of cells belonging to both the adaptive
and innate immune systems. Although considerable prog-
ress has been made in understanding the regulatory role
of subsets of T lymphocytes in this process (Paust and
Cantor, 2005), the contribution of innate immune mecha-
nisms to self-tolerance is less well defined.
The ability of natural-killer (NK) lymphocytes to recog-
nize and efficiently lyse activated T cells in vitro may allowthese cells to participate in this process, e.g., through in-
hibition of clonal expansion of T cells activated by foreign
or self-antigens in vivo (Rabinovich et al., 2003; Xu et al.,
2005). NK cells may also downregulate adaptive immune
responses through elimination of antigen-presenting den-
dritic cells (DCs) or through production of inhibitory cyto-
kines (Piccioli et al., 2002). One approach to defining the
regulatory role of NK cells comes from the finding
that NK cell activation is tightly constrained by an inter-
action between Qa-1–Qdm (Qa-1 determinant modifier,
AMAPRTLLL) ligands on target cells and inhibitory
CD94–NKG2A receptors on activated NK cells, here
termed the Qa-1–NKG2A interaction (Vance et al., 1998).
The Qa-1–Qdm ligand is a heterodimer composed of
the major histocompatibility complex (MHC) class Ib
molecule Qa-1 (H2-T23; the murine homolog of human
leukocyte antigen-E [HLA-E]), b2m, and peptides derived
in TAP-dependent fashion from the MHC class I leader
sequences (Qdm) (Aldrich et al., 1992; Lo et al., 1999,
2000; Sullivan et al., 2002). The interaction between
Qa-1–Qdm and CD94–NKG2A generally inhibits NK (or
CD8+ CTL) activity (Moser et al., 2002). Although Qa-1 is
expressed in many cell types at the RNA level (Transy
et al., 1987), expression of the Qa-1–Qdm surface protein
is restricted to activated T and B lymphocytes and
dendritic cells (Soloski et al., 1995; Sullivan et al., 2002),
allowing this ligand to selectively mark the central triad
of immunological cells.
We tested the hypothesis that an inhibitory interaction
between the class Ib MHC molecule Qa-1–Qdm on acti-
vated T cells and the CD94–NKG2A receptor on NK cells
(1) protects activated T cells fromNK lysis and (2) is essen-
tial for clonal expansion and development of immunologic
memory by self-reactive T cells. We found that Qa-1-
deficient CD4+ T cells failed to undergo antigen-induced
or homeostatic expansion secondary to increased sus-
ceptibility to lysis by a defined subset of NK cells. Further,
lentiviral-mediated expression of Qa-1–Qdm on autoreac-
tive CD4+ T cells rescued expansion of self-reactive T cell
clones whereas antibody-dependent interruption of the
Qa-1–NKG2A interaction dampened development of
experimental autoimmune encephalomyelitis (EAE).Immunity 26, 593–604, May 2007 ª2007 Elsevier Inc. 593
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Qa-1-Dependent Protection of Adaptive ImmunityFigure 1. Proliferation of Qa-1 WT and Qa-1-Deficient CD4+ T Cells
(A) CD4+ T cells isolated fromeither C57BL/6 (B6)Qa-1WTor B6Qa-1-deficient (N11)micewere transferred into syngeneicRag2/ orRag2/Prf1/
hosts. 14 days later, CD4+ T cells from spleen and LN were enumerated. Data are from one representative experiment of three in which each group
consisted of 3–4 mice. Graphs show mean ± SD (n = 3).
(B) Purified Qa-1WT or Qa-1-deficient OTII CD4+ T cells were transferred (106/mouse) into Rag2/ or Rag2/Prf1/ hosts along with immunization
of 50 mgOVA peptide emulsified in CFA. Proliferation of OTII cells wasmonitored by enumeration of CD4+Vb5
+ cells in LN and spleen 14 days later. NK
cells (0.53 106) purified from splenocytes ofRag2/mice were cotransferred with Qa-1-deficient OTII cells intoRag2/ Prf1/ hosts, as indicated.
Data are from one representative experiment of three in which each group consisted of 3–4 mice. Graphs show mean ± SD (n = 3).
(C) Peripheral T cell numbers in B6 Qa-1WT and Qa-1-deficient mice: Total numbers of CD4+ and CD8+ T cells from pooled spleen and lymph node of
5- to 6-week-old Qa-1-deficient (KO) mice or its wild-type (WT) littermates (4–6 mice/group). Graphs show mean ± SD (n = 4).
(D) Qa-1-deficient or WT mice were thymectomized (TX) or sham thymectomized at around 10 weeks age. The numbers of CD4+ and CD8+ cells
in peripheral lymphoid tissues 6 weeks after either thymectomy or sham thymectomy of Qa-1 WT or Qa-1-deficient mice at 10 weeks of age
(3 mice/group) were measured. Data shown represent the average of 3 pooled mice.RESULTS
Defective Expansion of Qa-1-Deficient CD4+
T Cells by NK Lysis
We initially defined the contribution of Qa-1 to protect
expanding CD4+ T cells from NK lysis in Rag2-deficent
hosts. Qa-1-deficient CD4+ T cells failed to undergo
homeostatic expansion over a 2 week period in Rag2/
hosts, in contrast to vigorous expansion by Qa-1 wild-
type (WT) CD4 cells. Defective expansion of Qa-1-
deficient CD4 cells in Rag2/ (NK cell-sufficient) hosts
was restored in Rag2/Prf1/ (NK cell-deficient) hosts
(Figure 1A). Expansion of Qa-1-deficient CD4+ T cells
expressing the OTII T cell receptor (TCR), specific for
chicken ovalbumin (OVA) 323-339 peptide bound to
MHC class IIb, was also severely impaired in Rag2/
hosts and restored in Rag2/Prf1/ hosts. This model
measures antigen-dependent expansion of CD4 cells
because significant numbers of OTII CD4+ T cells were
not recovered at day 7 and 14 unless OVA peptide was594 Immunity 26, 593–604, May 2007 ª2007 Elsevier Inc.provided at day 0. Perforin-dependent reduction of Qa-
1-deficient CD4+ T cells in Rag2/ hosts depended on
NK cells, because Rag2/Prf1/ hosts reconstituted
with purified NK cells prevented antigen-induced expan-
sion of Qa-1-deficient OTII+ CD4 cells (Figure 1B). Thus,
expression of Qa-1 protected activated CD4 cells from
NK lysis and was essential for both homeostatic and
antigen-induced CD4-cell expansion.
Decreased Lifespan of Qa-1-Deficient CD4+ T Cells
An important prediction of the hypothesis that Qa-1 ex-
pression on CD4 cells protects them from NK-dependent
destruction in vivo is that Qa-1-deficient mice should har-
bor reduced numbers of CD4 cells. However, examination
of adult Qa-1-deficient mice did not reveal this phenotype
(Figure 1C). Possibly, continuous resupply of T cells from
the thymus compensated for NK-dependent elimination
of Qa-1-deficient T cells in peripheral tissues. If so, re-
moval of the thymus from adult Qa-1-deficient mice might
uncover this phenotype. This was indeed the case. Within
Immunity
Qa-1-Dependent Protection of Adaptive ImmunityFigure 2. Cytokine Recall Response upon OTII Peptide Immunization
Qa-1WT or Qa-1-deficient mice bearing the OTII TCR transgene were immunized with 25 mg OVA peptide emulsified in CFA. 14 days later, OTII CD4+
T cells were purified from draining LN. To deplete NK cells, one group of mice was injected i.v. with NK1.1 antibody (200 mg/mouse) at day1 and day
6 after peptide immunization. Control mice were injected with PBS (3–4 mice/group).
(A) Increasing numbers of purifiedCD4+ T cells were stimulated in vitro with OVA peptide (10 mg/ml) and irradiated splenocytes (43 105). Supernatants
were collected 48 hr later and tested for IFN-g by ELISA. Data shown represent mean ± SD (n = 3).
(B) Purified OTII CD4+ T cells (13 105) were stimulated with the indicated concentrations of OVA peptide before collection of culture supernatant 48 hr
later and testing for IFN-g by ELISA. Data shown represent mean ± SD (n = 3).6 weeks after thymic ablation, Qa-1-deficient mice dis-
played a substantial (>85%) reduction in CD4+ T cells
compared with Qa-1 WT mice (Figure 1D). Thus, expres-
sion of Qa-1 was essential to ensure an unimpaired life-
span of CD4 cells in peripheral tissues.
The Contribution of Qa-1 Expression to Memory
Development by CD4 Cells
Impaired antigen-induced expansion of Qa-1-deficient OTII
CD4+ T cells in Rag2/ but not Rag2/Prf1/mice sug-
gested thatQa-1expressionprotectsactivatedCD4+Tcells
from perforin-dependent killing. We studiedmemory devel-
opment in mice that express the OTII TCR. Virtually all
peripheralT cells inOTIIC57BL/6 (B6)miceareCD4+Tcells,
and thesemice lack CD8+ T cells. After in vitro OVA peptide
restimulation of purified CD4+ T cells from OVA-immune
OTII donor mice, Qa-1-deficient CD4+ T cells displayed
a >90% reduction in IFN-g responses. This reflected
increased susceptibility of Qa-1-deficient CD4+ T cells to
NK lysis,becauseantibody-dependentdepletionofNKcells
during invivoprimingallowedQa-1-deficientCD4+Tcells to
develop unimpaired peptide-recall responses (Figures 2A
and2B). Analysis of the cytokine responseofQa-1-deficient
or Qa-1 WT OTII CD4+ T cells 7–10 days after injection into
Rag2/Prf1/ hosts along with OTII peptide showed that
the recall IFN-g response of the two groups of CD4+ T cells
was indistinguishable (Figure S1 in the Supplemental Data
available online). Thus, Qa-1 expression was essential for
the development of CD4+ T cell memory responses after
antigen stimulation in vivo.
Defective Responses of Qa-1-Deficient CD4+ T Cells
to Antigen in BM Chimeras
Loss of Qa-1 expression by hematopoietic cells in Qa-1-
deficient mice might enhance NK reactivity, as noted forMHCclass Ia antigens, or otherwise alter NK-cell develop-
ment. To address this issue, we analyzed mixed bone-
marrow (BM) chimeras containing both Qa-1+ and Qa-1
hematopoietic cells. Lethally irradiated Rag2/ mice
were reconstituted with Qa-1 WT (Thy1.1) plus Qa-1-
deficient (Thy1.2) BM and analyzed 4 or 12 weeks later.
The numbers of Qa-1-deficient CD4+ (and CD8+) lympho-
cytes were reduced at 4–6 weeks in Rag2/ but not
Rag2/Prf1/ hosts. However, by 12 weeks of BM
reconstitution, the numbers of Qa-1-deficient CD4+ T cells
were similar to that of Qa-1 WT CD4+ T cells (Figure 3A),
similar to studies of intact Qa-1-deficient mice that
indicated continuous T cell replenishment by the thymus
(see Figures 1C and 1D). We then compared the impact
of antigen stimulation on the Qa-1-deficient and Qa-1
WT cohorts of CD4+ T cells in these BM chimeras.
Although both Qa-1 WT and Qa-1-deficient CD4 cells
were well represented in these chimeric mice (Figure 3B),
after immunization with PLP peptide, only Qa-1 WT
CD4+ T cells responded to peptide restimulation as
judged by IFN-g production (Figure 3C). Further analysis
of CD4+ T cells in these BM chimeras showed that the
Qa-1+ fraction of CD4+ T cells expressed substantially
higher amounts of CD44 and CD5 (Figure 3D). Thus,
expression of Qa-1 was essential to allow antigen-stimu-
lated CD4+ T cells to develop memory activity as judged
by surface markers and cytokine recall responses.
Defective EAE Induction by Qa-1-Deficient CD4+
T Cells Reflects Susceptibility to NK Lysis
To investigate the potential impact of Qa-1–NKG2A inter-
actions on expansion of autoreactive CD4+ T cells and
consequent autoimmune disease, we analyzed the
response of CD4+ T cells that express a transgenic TCR
(2D2) specific for myelin oligodendrocyte glycoproteinImmunity 26, 593–604, May 2007 ª2007 Elsevier Inc. 595
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Qa-1-Dependent Protection of Adaptive ImmunityFigure 3. Development and Function of Qa-1 WT and Qa-1-Deficient T Cells in Mixed Bone-Marrow Chimeras
(A) Hematopoietic stem cell (HSC)-enriched bone-marrow cells (106/mouse) from Qa-1 WT (Thy1.1) and Qa-1-deficient (KO; Thy1.2) mice was co-
transferred into Rag2/ or Rag2/Prf1/ hosts and sacrificed at 4 or 12 weeks after transfer (4 mice/group). The total number of peripheral
CD4+ and CD8+ T cells from spleen and LN were enumerated. Data shown represent the average of 3 pooled mice.
(B) BM chimeric hosts were immunized subcutaneously with PLP peptide 12 weeks after adoptive transfer of BM cells. 14 days after immunization,
total CD4+ and CD8+ T cell numbers in draining LN were enumerated. Data shown represent the average of 3 pooled mice.
(C) Pooled (n = 3) Qa-1WT (Thy1.1) and Qa-1-deficient (Thy1.2) CD4+ T cells were purified from draining LN and stimulated with PLP peptide together
with irradiated splenocytes. IFN-g secretion was measured after 48 hr.
(D) The indicated subset of CD4+ T cells from the draining LNwere analyzed for CD44 and CD5 expression by FACS. Gated on CD4 cells: the solid line
represents Thy1.1 (WT); the dotted line represents Thy1.2 (KO).(MOG) autoantigen and induce EAE in adoptive hosts
(Bettelli et al., 2003). Transfer of 2D2 CD4+ T cells (106)
into Rag2/ hosts stimulated with 10 mg of MOG peptide
and pertussis toxin resulted in fulminating EAE that was
lethal within 3 weeks. In contrast, Rag2/ mice reconsti-
tutedwithQa-1-deficient 2D2CD4+ T cells developed little
or no disease after challenge with MOG–Complete
Freund’s Adjuvant (CFA) and pertussis toxin (Figure 4A).
Defective responses of Qa-1-deficient autoreactive CD4
cells reflected increased susceptibility to perforin-depen-
dent lysis, because Rag2/Prf1/ hosts reconstituted
with 2D2+ Qa-1 or Qa-1+ CD4 cells developed robust
EAE that led to death in approximately 3 weeks after
disease induction. Finally, Qa-1-dependent protection of
autoreactive T cells from NK lysis was not limited to lym-
phopenic Rag2/ hosts. Intravenous transfer of 2D2
Qa-1 WT CD4+ T cells but not 2D2 Qa-1-deficient CD4+
T cells induced EAE in C57BL/6 recipients (Figure 4B).596 Immunity 26, 593–604, May 2007 ª2007 Elsevier Inc.Thus, Qa-1 expression by pathogenic autoreactive CD4+
T cells was essential for protection of these cells against
perforin-dependent lysis and allowed them to induce
EAE in both C57BL/6 WT and C57BL/6 Rag2/ hosts.
Lentiviral-Mediated Expression of Qa-1–Qdm
Confers Protection to CD4+ T Cells
The findings that (1) responses of Qa-1-deficient CD4+
T cells to foreign and self-antigens were defective in
Rag2/Prf1/ hosts and (2) depletion of NK cells re-
stored peptide-recall responses of Qa-1-deficient mice
and enhanced the CD4 response in Qa-1 WT OTII mice
suggest that Qa-1–Qdm expression by CD4+ T cells may
protect them from NK lysis. To further evaluate this
hypothesis, we analyzed antigen-dependent responses
of Qa-1 WT OTII CD4+ T cells in Rag2/ or Rag2/
Prf1/ hosts. Expansion of OTII cells in Rag2/ was
delayed compared to Rag2/Prf1/ hosts, and the
Immunity
Qa-1-Dependent Protection of Adaptive ImmunityFigure 4. Reduced Ability of Qa-1-Deficient 2D2 CD4+ T Cells to Transfer EAE into Rag2/ Mice
(A) 2D2 CD4+ T cells (13 106) from either Qa-1 WT or Qa-1-deficient mice were transferred into syngeneic Rag2/ or Rag2/Prf1/mice (5 mice/
group) immunized with MOG 35–55 and CFA and pertussis toxin. Development of EAE was scored as described in Experimental Procedures. The bar
graph represents the disease incidence of the different groups.
(B) 2D2 CD4+ T cells (1 3 106) from either Qa-1 WT or Qa-1-deficient mice were transferred into C57BL/6 hosts (5 mice/group) followed by immu-
nization with (150 mg) MOG 35–55 peptide with pertussis toxin on the same day and day 2 to induce EAE. The development of EAE is shown, as
in (A), and disease incidence of the different groups is shown in the bar graph.
(C) Antigen-driven proliferation of OTII cells inRag2/ andRag2/Prf1/ hosts. OTII CD4+ T cells (13 106) were transferred intoRag2/ orRag2/
Prf1/mice (4 mice/group) before immunization with OVA peptide (75 mg peptide–CFA) immediately after transfer. Mice were taken down 72 hr later,
and total OTII cells in the draining LN and spleen were enumerated. On the right panel, OTII CD4+ T cells infected with lentivirus expressing either GFP
control or Qdm-b2m-Qa-1 fusion protein were also transferred into Rag2
/ or Rag2/Prf1/ hosts (4 mice/group) before immunization with OVA
peptide (75 mg peptide–CFA). 72 hr later, expansion of OTII cells was analyzed as described above. Data shown represent mean ± SD of the recovery
OTII CD4+ T cells from draining lymph nodes.numbers of OTII cells in draining LN of Rag2/mice were
reduced by more than 50% on day 3 after stimulation
compared with Rag2/Prf1/ hosts (Figure 4C). More
importantly, expression of a Qdm–b2m–Qa-1 fusion pro-
tein by OTII cells restored proliferation of OTII cells in
Rag2/ hosts to amounts similar to that observed in
Rag2/Prf1/ hosts (Figure 4C, right), directly supporting
the hypothesis that antigen-induced proliferation of T cells
requires Qa-1–Qdm-dependent protection from NK lysis.
Qa-1-Deficient Activated CD4+ T Cells Are Regulated
by the NKG2A+ Subset of NK Cells
About half of NK cells from C57BL/6 mice expressed
NKG2A (NKG2A+ NK cells) and half did not (NKG2A NKcells); both NKG2A phenotypes were stable after 1 week
of in vitro culture with IL-2 (Figure S2A). We then tested
these cells for lysis of Qa-1-deficient and WT CD4 cells
(see Experimental Procedures). The NKG2A+ but not
NKG2A NK-cell subset lysed Qa-1-deficient cells (Fig-
ure 5A). This finding indicated that lytic activity is
invested in an NK subset that expresses NKG2A+ and
therefore can bind to Qa-1–Qdm. The implications of this
finding require further investigation. Although NKG2A
NK1.1+ cells did not lyse Qa-1-deficient CD4+ T cells,
they efficiently lysed H-2Kb-deficient CD4+ T cells in a
Qdm peptide-independent fashion (Figure S1). The
NKG2A+ subsets also lysedH-2Db-deficient cells because
of the lack of Qdmpeptide. Lysis was inhibited by additionImmunity 26, 593–604, May 2007 ª2007 Elsevier Inc. 597
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Qa-1-Dependent Protection of Adaptive ImmunityFigure 5. In Vitro Lysis of Qa-1-Deficient CD4+ T Cells by IL-2-Activated NKG2A+ NK Cells
(A) NKG2A+ and NKG2A NK cells isolated from B6mice and activated individually by IL-2 were used at the indicated E:T ratios as effector killer cells
to kill ConA-activated CD4+ T cells fromQa-1wild-type andQa-1-deficient mice in a standard killing assay. This experiment is representative of a total
of four experiments. Data shown represent mean ± SD (n = 3).
(B) Protection of Qa-1-deficient CD4 cells from NK lysis by lentiviral-mediated surface expression of a covalent Qdm-b2m-Qa-1 complex. Qa-1-
deficient (Qa-1 KO) OTII cells were infected with lentivirus expressing either a Qdm-b2m-Qa-1 fusion protein (QbQ) or a HSP60 peptide-b2m-Qa-1
fusion protein (HbQ) and used as target cell in the killing assay by NKG2A+ NK cells. Qa-1 WT and Qa-1-deficient OTII cells were used as control.
Percentage of killing is shown at the indicated E:T ratios.
(C) CD4 cells were purified from Qa-1 WT and Qa-1-deficient OTII TCR transgenic mice, and splenic DCs were purified from Qa-1 WT and Qa-1-
deficient mice and activated by anti-CD40. NKG2A+ and NKG2A NK cells were purified from B6 mice and stimulated with 1000 U/ml IL-2 for
5 days. OTII CD4+ T cells (5 3 104) were stimulated with 1 mg/ml OVA peptide and 2.5 3 104 activated DC. The indicated numbers of IL-2-activated
NK cells were added to cultures 48 hr before proliferation of CD4+ T cells was measured. Data shown represent mean ± SD (n = 3).
(D) Adoptive transfer and homeostatic expansion of NK cells. NKG2A and NKG2A+ NK cells were purified from the spleens of B6 mice by FACS
sorting and injected i.v. (5 3 105) into Rag2/gc-deficient mice. 10 days later, spleens of host mice were analyzed for NK cells by staining with
antibodies against NK1.1 and NKG2A. This result represents three different experiments with 3–4 mice/group.of Qdm peptide (which reconstituted the Qa-1–Qdm com-
plex on H2-Db-deficient cells). The addition of Qdm pep-
tide also partially inhibited lysis of H-2KbDb double-defi-
cient cells by NKG2A+ NK cells but not by NKG2A NK
cells (Figures S2B and S2C). In addition, the lytic activity
of NKG2A+ and NKG2A NK cells against MHC-deficient
target L cells was similar to that exerted against H-
2KbDb-deficient target cells: both NK subsets lysed L cells
equally well, and lysis by NKG2A+ cells was partially in-
hibited by expression of Qa-1–Qdm (Figure S2D).
Increased susceptibility of Qa-1-deficient CD4+ T cells
to NK-cell lysis reflected defective expression of surface
Qa-1–Qdm (rather than altered development of CD4+
T cells in Qa-1-deficient mice), because lentiviral-
dependent re-expression of Qa-1 heavy chain covalently
attached to a Qdm peptide efficiently restored resistance598 Immunity 26, 593–604, May 2007 ª2007 Elsevier Inc.of Qa-1-deficient cells to NK lysis (Figure 5B). In contrast,
lentiviral introduction of Qa-1 heavy chain covalently
linked to a different peptide (from HSP60) did not protect
these cells (Figure 5B). These findings indicated that pro-
tection of CD4+ T cells was mediated by the Qa-1–Qdm
ligand rather than Qa-1 complexed to other peptides.
The hypothesis that the NKG2A+ fraction of NK cells is
selectively equipped to monitor cellular Qa-1–Qdm ex-
pression was supported by an examination of the regula-
tory activity of NK-cell subsets. Titration of NKG2A+ but not
NKG2A NK cells into cultures containing Qa-1-deficient
or Qa-1 WT OTII CD4 cells revealed a dose-dependent
inhibition of the former response by NKG2A+ but not
NKG2A NK cells (Figure 5C).
The surface phenotype and function of both NK subsets
were stable after 5 days in culture in the presence of IL-2
Immunity
Qa-1-Dependent Protection of Adaptive ImmunityFigure 6. NK Killing Susceptibility of
Qa-1-Deficient Cells Can Be Mimicked
by a Point Mutation at R72 that Disrupts
Its Binding to NKG2A
(A) NK cell susceptibility of R72A mutant
CD4 cells. CD4+ T cells from Qa-1 WT, Qa-1-
deficient, and Qa-1-R72A mutant mice were
activated by ConA for 48 hr, labeled with
51Cr, and used as targets for IL-2-activated
NKG2A+ and NKG2A NK cells in a standard
4 hr killing assay. Percentage of killing at E:T
ratio of 20:1 is shown. Data shown represent
mean ± SD (n = 3).
(B) Homeostatic expansion of R72A mutant CD4 cells. CD4+ T cells (1 3 106) were isolated from Qa-1 WT, Qa-1-deficient, and Qa-1-R72A mutant
mice and i.v. transferred into Rag2/ and Rag2/Prf1/ host (3 mice/group). 14 days later, host mice were killed and total CD4+ T cells were enu-
merated from spleen and LN. Data shown represent mean ± SD (n = 3).in vitro (Figure S1). Because NK cells, like other lympho-
cytes, undergo homeostatic expansion in lymphopenic
hosts, we transferred NKG2A+ or NKG2A NK cells into
Rag2/ common g chain (gc)-deficient hosts to evaluate
the stability of the NKG2A+ subset in vivo. 2 weeks after
adoptive transfer of purified NKG2A+ NK1.1 cells into
Rag2/gc-deficient hosts, these cells maintained ex-
pression of NKG2A on their surface, indicating that the
NKG2A+ phenotype marks a stable subset of NK cells
in vivo (Figure 5D). Because NK cells developing from fetal
progenitors acquire expression of NKG2A and Ly49 in
a random manner, differential expression of Ly49 gene
products on NKG2A+ and NKG2A NK cells might account
for their ability to lyse ‘‘activated self’’ targets. NKG2A+
and NKG2ANK cells may also express different amounts
of activating receptors such as NKG2D (Rabinovich et al.,
2003). Examination of Ly49C+I expression by NKG2A+
and NKG2A NK cells indicated that roughly 2/3 of each
NK subset is Ly49I+C. Whether the inhibitory Ly49C+I re-
ceptor might regulate lysis ofMHC class I+–Qa-1-deficient
target cells by NKG2A+ NK cells requires further study.
Selective Disruption of the Interaction between Qa-1
and CD94-NKG2A by a Point Mutation
We have shown that Qa-1-deficient CD4+ T cells were
susceptible to lysis by NKG2A+ NK cells and failed to
develop immunological memory in vivo. However, genetic
deletion of Qa-1 and insertion of a Neor gene into theMHC
class I locus might affect expression of linked MHC genes
or alter surface protein display in a way that increases cel-
lular susceptibility to lysis. A direct molecular approach to
this question came from the definition of a Qa-1 amino
acid mutation that eliminated binding activity to the
CD94–NKG2A receptor but spared other Qa-1-dependent
biological activities.
The solved structure of the human HLA-E molecule and
mutagenic analysis of its interaction with CD94–NKG2
molecules (Wada et al., 2004) allowed us to identify poten-
tial residues that may be essential for the Qa-1 interaction
with CD94–NKG2A but do not interfere with its interaction
with the T cell receptor. These residues included R65,
D69, Q72, R75, R79, H155, D162, and E166, which are
conserved in the mouse Qa-1 molecule. Five Qa-1 muta-
tions (D69A, R72A, R75A D162A, and E166A) were testedfor their impact on the functional interaction of Qa-1 with
CD94–NKG2A. The R72 residue at the top of the a1 do-
main of Qa-1 was the most critical for functional interac-
tionswith theCD94–NKG2A receptor: Qa-1 R72Amutants
failed to protect L cells from lysis by NKG2A+ NK cells but
were fully able to target Qa-1-specific alloreactive CD8 T
cell lysis (Figures S3A and S3C). Mutations of Qa-1 at
R75, D162, and E166 did not impair Qa-1–NKG2A interac-
tions, and these Qa-1 mutants fully protected L cells from
NKG2A+ NK-cell lysis (Figures S3A and S3B). Finally,
although the D69A mutation impaired protection from
NK lysis, this mutation also interfered with detection of the
molecule by Qa-1 antibody and was therefore not chosen
for further study (Figures S3A and S3B).
Qa-1 R72A Mutant Knockin Mice Display
the Qa-1-Deficient Phenotype
We generated Qa-1 R72A mutant knockin mice by using
the cre-loxP system (Figures S4A and S4B). Although
the R72A mutant was expressed on activated T cells at
amounts similar to the WT protein in WT mice
(Figure S4C), Qa-1 R72A mutant T cells were no longer
protected from NK lysis and were as vulnerable as Qa-1-
deficient T cells (Figure 6A). Next, CD4+ T cells from Qa-1
R72A mutant mice were transferred into Rag2/ and
Rag2/Prf1/ hosts and examined for homeostatic
expansion. CD4+ T cells expressing the Qa-1 R72A point
mutation expressed the phenotype of Qa-1-deficient cells
and failed to expand in Rag2/ hosts but expanded
as well as Qa-1 WT cells in Rag2/Prf1/ hosts
(Figure 6B). These results reinforced findings with Qa-1-
deficient mice that Qa-1-dependent protection of CD4+
T cell expansion and adaptive memory responses de-
pends entirely on its interaction with CD94–NKG2A. The
generation and validation of Qa-1 R72A mutant mice
also provided a unique mouse model to examine the func-
tional outcome of defective Qa-1–NKG2A interactions
on immune responses without affecting other antigen-
presenting properties of the Qa-1 molecule.
Antibody-Dependent Blockade of Qa-1–NKG2A
Interaction Inhibits Development of EAE
To determine whether blockade of this interaction with
Qa-1 antibody inhibits the development of EAE, weImmunity 26, 593–604, May 2007 ª2007 Elsevier Inc. 599
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of EAE
EAE were induced in C57BL/6 mice as
described in Experimental Procedures via
MOG peptide. Qa-1 antibody was injected i.v.
(200 mg/injection) at days 5, 9, and 12 after
peptide immunization. In a separate group,
anti-NK1.1 was administered (150 mg, i.v.) at
days 3, 6, and 10 to deplete NK cells with or
without injection of Qa-1 antibody on days 5,
9, and 12, as above. Control groups were
injected with either PBS or mouse IgG1 isotype
control antibody (5 mice/group). The develop-
ment of disease was monitored as described
in Experimental Procedures. Data shown
represent two independent experiments.administered Qa-1 antibody to mice during the period
preceding clinical signs of disease and preceding the
development of Qa-1-restricted CD8+ regulatory T cells
(Jiang et al., 1992; Hu et al., 2004). This protocol markedly
reduced the intensity of EAE. The therapeutic effects of
Qa-1-antibody injection depended on the action of NK
cells, because hosts depleted of NK cells with NK1.1 an-
tibody did not display a therapeutic response to treatment
with Qa-1 antibody (Figure 7). These observations indicate
that the autoimmune CD4+ T response responsible for
EAE can be almost fully ameliorated by antibody-depen-
dent blockade of theQa-1–NKG2A interaction and associ-
ated NK-dependent elimination of pathogenic T cells.
Although murine Qa-1 is structurally similar to human
HLA-E, potential differences in surface expression (Lee
et al., 1998) and increased numbers of MHC peptides
stabilized by HLA-E compared with murine Qa-1 needs
to be taken into consideration when applying thesemurine
findings to studies of the interaction of HLA-E and human
NK cells.
DISCUSSION
Activation of T cells is thought to be regulated by cells be-
longing to both the adaptive and innate immune systems.
Although the role of CD25+ Foxp3+ CD4+ regulatory T cells
has been the object of intense study, the regulatory activ-
ity of cells belonging to the innate immune system has
been given less experimental attention. Although analyses
of murine autoimmune disease models have indicated
that depletion of NK cells can augment EAE (Zhang
et al., 1997; Xu et al., 2005), whereas activation of NK cells
can inhibit disease (Wang et al., 2006), the mechanism
responsible for these effects is not well understood. NK
cells are equipped to recognize and lyse activated T cells
(Rabinovich et al., 2003; Gasser et al., 2005), and inter-
actions between NK cells and antigen-presenting cells
may inhibit the activation of T helper cells (Gerosa et al.,
2002; Martin-Fontecha et al., 2004). NK cells also produce
inhibitory cytokines that canmodulate immunity (Mehrotra
et al., 1998).600 Immunity 26, 593–604, May 2007 ª2007 Elsevier Inc.To define the molecular basis of Qa-1-dependent pro-
tection, we generated Qa-1 knockin mice that express
an amino acid exchange mutation (R72A) that eliminates
Qa-1 binding to CD94–NKG2A but spares binding to the
TCR and CD8 coreceptor. Activated Qa-1 R72A CD4+
T cells were highly susceptible to lysis by NKG2A+ NK
cells and failed to expand in vivo, which provides molecu-
lar confirmation of the role of the Qa-1–NKG2A interaction
in protection of CD4+ T cells from NK lysis. Dissection of
the NK cell population revealed that the NKG2A+ but not
NKG2A subset of NK cells mediate lysis of Qa-1-deficient
CD4 cells. An important therapeutic corollary of these
findings is that blockade of the Qa-1–NKG2A interaction
that constrains NK lysis of activated T cells after immuni-
zation should result in potent NK-dependent elimination
of activated autoreactive T cells and amelioration of auto-
immune disease in EAE. This proved to be the case. These
findings extend the functional reach of the NK system to
include regulation of adaptive T cell responses and sug-
gest that antibody-mediated blockade of Qa-1–NKG2A
interactions represents a new clinical approach for elimi-
nation of antigen-activated T cells in the context of auto-
immune disease or transplantation.
Qa-1 associated with its dominant peptide Qdm is the
major ligand of the CD94–NKG2A receptor. Expression
of Qa-1–Qdm on the surface of activated T cells may pro-
vide a sensitive monitor of altered or diminished MHC ex-
pression to NK cells after viral infection or transformation.
This system is analogous to the classical interaction of
Ly49 receptor isoforms with endogenous class I mole-
cules that lead to a negative signal for NK cytotoxicity
(Karlhofer et al., 1992; Litwin et al., 1994) and which may
regulate NK interactions with developing thymocytes
(Schott et al., 2003). Although decreasedMHC class Ia ex-
pression after viral infection or cell transformation can in-
crease susceptibility to NK lysis, this process may not
be as efficient as alterations in Qa-1–Qdm expression,
which has an increased off rate and shorter membrane
half-life (Kraft et al., 2000). As a result, reductions in newly
synthesized MHC molecules are likely to be sensed rela-
tively early by NKG2A+ NK cells that monitor the MHC sig-
nal peptide (Qdm) complexed toQa-1.We have previously
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regulatory CD8+ T cells (Hu et al., 2004). Here we used
cellular and genetic experimental approaches to study
the interaction between Qa-1–Qdm and CD94–NKG2A
through selective disruption of contact residues responsi-
ble for Qa-1 binding to CD94–NKG2A but not to CD8. A
second Qa-1 mutant knockin mouse defective in mediat-
ing Qa-1 CD8 binding but not CD94–NKG2A has been
generated to provide a simplified in vivo system that will
allow further dissection of the role of the Qa-1–NKG2A
and Qa-1–TCR interactions in immune regulation.
Because the level of activated NKG2A+ NK cells after
infection or deliberate immunization determined the
potency of NK-dependent inhibitory activity, certain infec-
tious stimuli associated with strong NK-cell activationmay
be particularly susceptible to NK-dependent regulation
(Wang et al., 1998). Alterations in the surface Qa-1–Qdm
expression on individual clones of CD4 cells after immuni-
zation will also determine their ability to expand in the face
of activated NK cells. Naive T cells, which do not express
significant surface levels of Qa-1–Qdm, are not lysed by
NKG2A+ NK cells, presumably because they fail to ex-
press stimulatory ligand(s) for NK-cell lysis (Raulet and
Vance, 2006). CD4+ T cells become transiently suscepti-
ble to NK-dependent elimination shortly after activation
(Rabinovich et al., 2003), perhaps through reductions in
the ratio of Qa-1–Qdm to Qa-1 bound to other peptides
that fail to interact with CD94–NKG2A (Lu et al., 2006).
This window of susceptibility is apparent in vivo from
enhanced CD4 responses to foreign or self-antigens after
NK-cell depletion.
In addition to the protective effects of Qa-1–Qdm on the
development of immunological memory, we have uncov-
ered a division of labor between NKG2A+ and NKG2A
NK cells. The ability to monitor T cells for expression of
an intact Qa-1–Qdm complex but diminished MHC class I
is invested in both subsets of NK cells. The NKG2A+,
but not NKG2A, NK subset is equipped to detect missing
Qa-1–Qdm-labeled complex on activated T cells and lyse
these target cells. Although NKG2ANK cells are not con-
strained by CD94–NKG2A-dependent inhibitory signals,
these cells are unable to lyse Qa-1-deficient target cells.
This does not reflect differential expression of Ly49 inhib-
itory and/or activation receptors on their surface (data not
shown). Although Ly49-dependent regulation of NK-cell
activity depends on in vivo education against the relevant
H-2 molecules, this may not to be the case for the Qa-1
ligand under the experimental conditions used here.
NKG2A+ NK cells from Qa-1-deficient mice displayed un-
impaired lytic activity against autologous activated CD4
cells, consistent with the substantially reduced levels of
T cells in Qa-1-deficient mice after elimination of new thy-
mic immigrants by thymectomy. What about the contribu-
tion of the NKG2A protein to lysis? It may be relevant that
human NK cells clones from hepatitis C virus-infected
human liver are divisible into functionally distinct subsets
according toNKG2Aexpression. NKG2A+ but not NKG2A
NK clones lyse vaccinia-infected autologous BLCL cells,
while both NKG2A+ and NKG2A clones lyse aMHC classI-negative parent BLCL cell line (Brooks et al., 2006).
Although NK cells from DBA/2J mice are naturally CD94
deficient, a preliminary analysis of NK cells from DBA/
2Ncr (CD94:NKG2A+) and DBA/2J (CD94:NKG2A) failed
to show a difference in NK lytic activity against autologous
activated CD4+ T cells in the presence of Qa-1 antibody
(not shown). Possibly, NKG2A NK cells either tolerate
Qa-1-deficient cells or are not educated to recognize
and lyse Qa-1-deficient target cells (Raulet, 2006).
Monoclonal antibody therapy to selectively deplete or
suppress activation of pathogenic T cells has had limited
success because of poor efficacy and potentially severe
side effects (Bach, 2006). These approaches have in-
cluded antibodies against CD3, which can induce activa-
tion-induced apoptosis of antigen-activated T cells, and
anti-CD28 or anti-CD40L, which can deplete activated
CD4+ T cells. Because these antibodies often retain stim-
ulatory or costimulatory properties, a frequent outcome of
their use is wholesale and sometimes massive release of
cytokines, leading to a ‘‘cytokine storm’’ (Suntharalingam
et al., 2006). Other nonselective antibodies that have been
tested in the clinic, including anti-CD52-dependent deple-
tion of T, B, NK, and monocytes, can lead to generalized
immunosuppression and associated opportunistic infec-
tions (Chatenoud, 2004), whereas anti-CD25-dependent
depletion of activated T cells is now known to affect
regulatory T cells as well.
Our findings suggest a new clinical approach for selec-
tive inhibition of activated pathogenic T cells that exploits
the NK-dependent physiological regulatory mechanism
delineated in this report. The use of antibody-dependent
blockade of the Qa-1–NKG2A interaction to allow NK-
cell-mediated elimination of activated CD4+ T cells has
several features that distinguish it from current therapies.
Current antibody-based approaches depend on direct ac-
tivation or depletion of pathogenic lymphocytes, whereas
interruption of the inhibitory Qa-1–NKG2A interaction to
unleashNK cell-dependent elimination of activated poten-
tially-pathogenic autoreactive cells (1) does not deliver
costimulatory signals and thus avoids the risk of cytokine
storm and (2) will not affect naive T cell populations and
thus should preserve immunocompetence. Because
propagation and exacerbation of disease is likely to
depend on continuous recruitment and activation of new
T cells and their subsequent differentiation into patho-
genic memory and effector cells, Qa-1–NKG2A blockade
after established disease may reduce disease severity
by inhibition of the continued development of effector cells
from newly arising autoreactive precursors.
The therapeutic effects of Qa-1–NKG2A blockade may
depend in part on the levels of NK-cell activation at differ-
ent stages of autoimmune inflammatory disease. Indeed,
the ability of IFN-a and IFN-b to ameliorate MS in humans
(Willenborg et al., 1996; Jacobs et al., 2000; Steinman and
Zamvil, 2006) and of IFN-g to inhibit EAE in mice (Durelli
et al., 1995) may reflect the ability of these cytokines to
transiently activate NK-dependent regulatory responses
(Edwards et al., 1985). However, because IFN treatment
also upregulates Qa-1 expression on T cells (Ota et al.,Immunity 26, 593–604, May 2007 ª2007 Elsevier Inc. 601
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these therapeutic effects may reflect a Qa-1-dependent
decrease in NK activation and associated immunoregula-
tory activity. Combined treatment with recombinant IFN
along with antibody-mediated interruption of Qa-1–
NKG2A interactions may allow more efficient and durable
therapeutic responses inMSpatients. Therapeutic disrup-
tion of Qa-1–NKG2A interaction in the context of auto-
immune disease might also inhibit recently activated T
cells specific for foreign antigens. Therefore, vaccination
against pathogens should be avoided during anti-Qa-
1-mediated therapy, and vaccine-induced memory re-
sponses against pathogens should be closely monitored
by skin testing. These and other therapeutic approaches
to autoimmune disease depend on additional molecular
insight into the regulatory interactions that govern NK
cell-dependent regulation of adaptive immune responses
described in this report.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6, Rag2/, Rag2/perforin (Prf1)/, Rag2/common
g chain (gc)-deficient mice, H-2KbDb-deficient, H-2Kb-deficient, and
H-2Db-deficient mice were purchased from Taconic Laboratories.
Qa-1-deficient mice were backcrossed onto C57BL/6 for at least 11
generations and have been described previously (Hu et al., 2004).
OTII TCR-transgenic mice provided by H. Ploegh (Harvard Medical
School, Boston, MA) were crossed with B6.Qa-1b-deficient mice.
C57BL/6 2D2 TCR transgenic mice express a TCR recognizing the
CNS auto-antigen MOG (Bettelli et al., 2003) and were crossed with
B6.Qa-1b-deficient mice. Mice were housed in a specific pathogen-
free, viral antibody-free animal facility at the Dana-Farber Cancer Insti-
tute. All experiments were done in compliance with federal laws and
institutional guidelines and have been approved by the Dana Farber
Cancer Institute Animal Care and Use Committee.
Antibodies
Purified mAbs against CD33 (145-2C11), CD8 (53-6.7), CD4 (GK1.5),
B220 (RA3-6B2), MAC-1 (M1/70), GR-1 (RB6-8C5), NK1.1 (PK136),
Ly49I/C, and FITC-conjugated anti-NKG2A/C/E were purchased
from Pharmingen. Purified and biotinylated-anti-NKG2AB6 were
purchased from eBiosicience. Anti-biotin and anti-DX5 beads were
purchased from Miltenyi Biotec (Auburn, CA).
Antigens
The peptide MOG 35–55 (MEVGWYRSPFSRVVHLYRNGK), OVA pep-
tide (amino acids 323–339; ISQAVHAAHAEINEAGR), and PLP peptide
(amino acids 172–183; PVYIYFNTwtTC) were synthesized by New
England Peptide (Gardner, MA).
CD4 and CD8 Cell Purification
CD4 and CD8 T cells were purified by negative selection after incuba-
tion for 30 min with rat anti-mouse CD8 (anti-CD8) or anti-CD4, in
addition to anti-B220, anti-Mac-1, anti-Gr-1, and anti-NK1.1 (BD Phar-
mingen). After washing, cells were incubated for 30 min with magnetic
beads coated with sheep anti-rat IgG (Dynal) before isolation of CD4
and CD8 T cells by magnetic separation.
Adoptive CD4 T Cell Transfer and Induction and Assessment
of EAE
2D2CD4 T cells purified from either Qa-1WT orQa-1-deficient mice as
described above were transferred i.v. (106) into Rag2/ or Rag2/
Prf1/ hosts that were immunized s.c. with 10 mg MOG 35–55 emul-
sified in CFA (supplemented with 4 mg/ml ofMycobacterium tubercu-602 Immunity 26, 593–604, May 2007 ª2007 Elsevier Inc.losis) and injected i.p. on days 0 and 2 with 200 ng pertussis toxin to
induce EAE. Clinical assessment of EAE was performed daily and
scoring was as follows: 0, no disease; 1, decreased tail tone; 2, hind
limb weakness or partial paralysis; 3, complete hind limb paralysis;
4, front and hind limb paralysis; 5, moribund state.
Bone-Marrow Transfer
BM cells were harvested from femur and tibia under sterile conditions
from Qa-1 WT (Thy1.1) or Qa-1-deficient (Thy1.2) mice, and erythro-
cytes were lysed and enriched for hematopoietic stem cells by
depletion of lineage-positive cells with anti-CD4, anti-CD8, anti-CD3,
anti-Gr1, anti-Mac1, anti-CD19, and anti-DX5 followed by sheep
anti-rat IgG-conjugated immunomagnetic beads (Dynal). Cells (1 3
106) were then injected into irradiated (400 rads) Rag2/ or Rag2/
Prf1/ mice.
Immunization and In Vitro Recall Response
OTII TCR transgenic Qa-1 WT or Qa-1-deficient mice were immunized
s.c. with 50 mg of OVA peptide (amino acids 323339; ISQAVHAA-
HAEINEAGR) in CFA. For NK-cell depletion, mice were injected with
200 mg purified NK1.1 antibody at day1 and day 6. 12 days after pep-
tide immunization, CD4 cells from draining lymph nodewere incubated
with different concentrations of OVA peptide and irradiated spleno-
cytes from B6 mice in RPMI 1640 medium supplemented with 10%
fetal calf serum and 50 mM b-mercaptoethanol. Culture supernatants
were collected after 48 hr of culture, and cytokine concentrations in
supernatants were determined by enzyme-linked immunosorbent
assay (ELISA) kit (BD Pharmingen).
NK-Cell Purification
Splenocytes were incubated with CD4, CD8, and B220 antibodies and
mixed with magnetic beads and separated by magnetic cell sorting.
For purification of NKG2A+ NK cells, the CD4, CD8, and B220 sple-
nocytes were stained with biotinylated NKG2AB6 mAb (eBioscience),
followed by incubation with magnetic microbeads coated with biotin
antibody (Mytech) before magnetic cell sorting with MACS. DX5
mAb was then used to further purify the NKG2A NK cell population
from the flow through cells. Purified NK cells were cultured in RPMI-
1640 supplemented with 10% FCS in the presence of 1000 U/ml
human recombinant IL-2 (BD Pharmingen) for 5 days.
NK Cytotoxic Assay
Target cells were labeled with 50 mCi of Na2(
51Cr)O4 for 1 hr at 37
C,
washed 3 times with PBS before mixing (1 3 104/well) with effector
cells in U-bottomed 96-well plates at different E–T ratios (10:1, 20:1,
40:1) in triplicate. After 4 hr of incubation, cell-free supernatants
were collected and radioactivity measured by Micro-b counter (Wal-
lac). Percentage of lysis is calculated by (sample release  spontane-
ous release)/(maximum release  spontaneous release).
Lentiviral Expression of Qa-1
Full-length ORF of Qa-1 was amplified by RT-PCR from ConA-
activated C57BL/6 spleen RNA, digested with BamHI-XhoI, and
cloned into pLenti6/V5 (Invitrogen) by using BamHI and XhoI restriction
sites. The construct was confirmed by sequencing. Enhanced GFP
alone was cloned into pLenti6/V5 as a negative control. For mutation
screening, a point mutation was introduced by site-directed muta-
genesis according to manufacturer’s instructions (Stratagene). For
expression of peptide sewed in Qa-1 molecules, Qdm–b2m–Qa-1
and HSP60–b2m–Qa-1 fusion proteins were made by overlapping
PCR (see Supplemental Data for protocol). Lentiviral stocks were gen-
erated by cotransfection of 293 T cells with the packaging plasmids
pLP1, pLP2, and pLP/VSVG (Invitrogen) via Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s protocol. Viral supernatants
were collected 72 hr after transfection and the viral titer for all transfec-
tions was approximately 107 plaque-forming units/ml. Naive Qa-1-de-
ficient CD4 T cells were infected with lentivirus at a moi of 5–10 for 3–6
hr at 37Cwith 5%CO2 and either washed and used directly after a 3 hr
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5% CO2.
Anti-Qa-1 Treatment and Induction of EAE
C57BL/6 mice were immunized s.c. with 150 mg MOG 35–55 emulsi-
fied in CFA (supplemented with 4 mg/ml ofMycobacterium tuberculo-
sis) and injected i.p. on day 0 and day 2 with 200 ng pertussis toxin to
induce EAE. To block theQa-1–NKG2A interaction, Qa-1 antibodywas
administered three times at day 5, 9, and 12 after immunization (200 mg,
i.v.). In a separate group, anti-NK1.1 was administered (150 mg, i.v.)
at day 3, 7, and 10 to deplete NK cells before administration of Qa-1
antibody on days 5, 9, and 12 to determine whether altered disease
development was NK-cell dependent or not. A control group was
given either PBS or mouse IgG1 isotype control (5 mice per group),
and clinical assessment of EAE was performed daily and scored as
described above.
Supplemental Data
Four figures are available at http://www.immunity.com/cgi/content/
full/26/5/593/DC1/.
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